Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Maureen Kenny

Executive Editor

London, UK
Maureen's expertise in bringing exclusive, business-critical content to the expanded Pink Sheet audience builds upon her many years' experience as an editor and reporter. Most recently, Maureen headed Scrip Regulatory Affairs, an indispensable publication for both pharmaceutical and medtech regulatory affairs professionals worldwide. She managed the publication's move from print to digital. Previous leadership roles also include being editor of Clinica Medtech Intelligence and acting editor of Scrip Intelligence. She chaired the DIA EuroMeeting plenary session in Paris in April 2015 and spent two years in New York covering the pharmaceutical industry in the US, Canada and, being a fluent Spanish speaker, Latin America. Maureen is based in London.
Advertisement
Set Alert for Articles By Maureen Kenny

Latest From Maureen Kenny

All Set For EU Approval: First Biosimilar Humalog And Three More Rituximabs From Celltrion

The European Medicines Agency has given the thumbs-up to Insulin lispro Sanofi, the first biosimilar version of Lilly’s diabetes drug Humalog. It has also green-lighted three more biosimilar rituximab products from Celltrion, which already has EU approval for one version of the originator product, Roche’s MabThera.

Biosimilars Approvals

Decade-Old Advanced Therapy Set For EU Approval

German company CO.DON is celebrating the fact that it probably won’t be long before it can start selling across Europe its key product – an advanced therapy for the repair of certain cartilage defects of the knee that’s been in use in Germany for ten years.

Germany Europe

Quest For ‘It Factor’ Continues In Competition For EMA After Brexit

The many cities that want to host the European Medicines Agency when it moves from London to another member state in light of Brexit are working hard to come up with a determining factor that will make them the obvious choice. It may on the surface seem strange, but Ireland is making much of the fact that if its capital city Dublin were chosen, existing EMA staff wouldn’t need to move there.

Europe Sweden

Rasi On Brexit: ‘EMA Is Well-Oiled Machine That We Cannot Afford To Start Stuttering’

European Medicines Agency head Guido Rasi tackles issue of Brexit in agency’s 2016 annual report, saying EMA is “core building block of the common market for medicines in the EU” that operates like “well-oiled machinery.”

Brexit Europe

Massive Reallocation of UK Rapporteurships Likely As EMA Plans For Future; UK’s Interim Role Uncertain

If Brexit means the UK no longer plays a part in the EU drug regulatory system, responsibility for the ongoing oversight of almost one in four of all the human medicines that have ever been approved under the centralized procedure will have to be reassigned from the UK to other member states. What Brexit means for the UK’s role as a key player in the regulatory system in the meantime is the subject of speculation.

Brexit Drug Review

AbbVie Scores HCV First Under UK’s Early Access Scheme

AbbVie’s investigational hepatitis C treatment has become the latest therapy to get the green light under the UK’s early access to medicines scheme. The scheme enables patients to access the treatment ahead of it receiving an EU marketing authorization.

Market Access Drug Review
See All
Advertisement
UsernamePublicRestriction

Register